Search results
18 lip 2023 · Patient-related prognostic factors include age and comorbidities. According to the Revised International Prognostic Scoring System (IPSS-R), age at diagnosis discernibly influences the prognosis of patients with low-risk MDS but has only a limited effect on those with high-risk MDS.
Survival statistics for MDS. The following survival statistics are divided by the Molecular International Prognostic Scoring System (IPSS-M) risk groups. Again, it’s important to note that this system is based largely on people who were diagnosed with MDS and treated many years ago.
Outcomes for patients with MDS are associated with certain clinical, pathologic, and molecular features. Assessment of prognosis is key to the selection of a management strategy and serves as a default staging system for MDS. This topic discusses risk factors and prognostic models for MDS.
Life expectancy with MDS can range depending on what type of MDS you have, how likely it is that the MDS will become leukemia, and other risk factors. Your doctor may use a scoring system to...
Patients in the very high risk group have a median survival time of only 0.8 years, whereas median survival for patients in the very low risk group is 8.8 years, hardly different from the life expectancy of the age-matched healthy population .
27 maj 2012 · The overall 3-year survival rate was 32%; lower for females than for males. Overall survival of patients with bone marrow blasts less than 10% is better than those which presented higher than 10% bone marrow blasts, with significant difference.
7 maj 2024 · At a median follow-up of 48 months (95% confidence interval [CI] 35–61 months), the median survival was 69 months (95% CI 59–79 months).
